Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Prognostic factors for worsening and improvement in multiple sclerosis using a multistate model.

Autor: Ocampo A; Novartis Pharma AG, Basel, Switzerland., Hatami F; Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK., Čuklina J; Novartis Pharma AG, Basel, Switzerland., Graham G; Novartis Pharma AG, Basel, Switzerland., Ganjgahi H; Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK.; Department of Statistics, University of Oxford, Oxford, UK., Sun Y; Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK., Su W; Novartis Pharmaceuticals, East Hanover, NJ, USA., Mousseau MC; Novartis Ireland Ltd, Dublin, Ireland., Gardiner S; Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK., Pendleton SC; Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK., Aarden P; Novartis Pharma AG, Basel, Switzerland., Kieseier BC; Novartis Pharma AG, Basel, Switzerland., Arnold DL; McConnell Brain Imaging Centre, Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada., Bermel RA; Mellen Center for Multiple Sclerosis, Department of Neurology, Cleveland Clinic, Cleveland, OH, USA., Häring DA; Novartis Pharma AG, Basel, Switzerland., Nichols TE; Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Medicine, Big Data Institute, University of Oxford, Oxford, UK., Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.; Brain and Mind Centre, The University of Sydney, Sydney, NSW, Australia.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Oct; Vol. 30 (11-12), pp. 1455-1467. Date of Electronic Publication: 2024 Sep 28.

The Development of Ofatumumab, a Fully Human Anti-CD20 Monoclonal Antibody for Practical Use in Relapsing Multiple Sclerosis Treatment.

Autor: Hauser SL; UCSF Weill Institute for Neurosciences, University of California, San Francisco, San Francisco, CA, USA. Stephen.Hauser@ucsf.edu., Kappos L; Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB) and MS Center, and Departments of Medicine, Clinical Research, Biomedicine and Biomedical Engineering, University Hospital of Basel, University of Basel, Basel, Switzerland., Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Wiendl H; Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany., Paling D; Sheffield Institute of Translational Neuroscience, Sheffield Teaching Hospital NHS Foundation Trust, Sheffield, UK., Williams M; Joi Life Wellness Multiple Sclerosis Neurology Center, Atlanta, GA, USA., Gold R; Department of Neurology, St Josef-Hospital/Ruhr-University Bochum, Bochum, Germany., Chan A; Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Milo R; Department of Neurology, Barzilai Medical Center, Ashkelon/Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel., Das Gupta A; Novartis Pharma AG, Basel, Switzerland., Karlsson G; Novartis Pharma AG, Basel, Switzerland., Sullivan R; Novartis Pharma AG, Basel, Switzerland., Graham G; Novartis Pharma AG, Basel, Switzerland., Merschhemke M; Novartis Pharma AG, Basel, Switzerland., Häring DA; Novartis Pharma AG, Basel, Switzerland., Vermersch P; Univ. Lille, INSERM U1172 LilNCog, CHU Lille, FHU Precise, 59000, Lille, France.

Publikováno v: Neurology and therapy [Neurol Ther] 2023 Oct; Vol. 12 (5), pp. 1491-1515. Date of Electronic Publication: 2023 Jul 14.

Serum Neurofilament Light Trajectories and Their Relation to Subclinical Radiological Disease Activity in Relapsing Multiple Sclerosis Patients in the APLIOS Trial.

Autor: Bar-Or A; Center for Neuroinflammation and Experimental Therapeutics and Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. amitbar@pennmedicine.upenn.edu., Montalban X; Department of Neurology-Neuroimmunology and Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain., Hu X; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Kropshofer H; Novartis Pharma AG, Basel, Switzerland., Kukkaro P; Novartis Pharma AG, Basel, Switzerland., Coello N; Novartis Pharma AG, Basel, Switzerland., Ludwig I; Novartis Pharma AG, Basel, Switzerland., Willi R; Novartis Pharma AG, Basel, Switzerland., Zalesak M; Novartis Pharma AG, Basel, Switzerland., Ramanathan K; Novartis Pharma AG, Basel, Switzerland., Kieseier BC; Novartis Pharma AG, Basel, Switzerland.; Department of Neurology, Medical Faculty, Heinrich-Heine University, Dusseldorf, Germany., Häring DA; Novartis Pharma AG, Basel, Switzerland., Bagger M; Novartis Pharma AG, Basel, Switzerland., Fox E; Central Texas Neurology Consultants and Dell Medical School, The University of Texas at Austin, Round Rock, Austin, TX, USA.

Publikováno v: Neurology and therapy [Neurol Ther] 2023 Feb; Vol. 12 (1), pp. 303-317. Date of Electronic Publication: 2022 Dec 19.

Simulated treatment comparison of efficacy outcomes for ofatumumab in ASCLEPIOS I/II versus ocrelizumab in OPERA I/II for the treatment of patients with relapsing multiple sclerosis.

Autor: Samjoo IA; EVERSANA™, Burlington, Ontario, Canada., Klotz L; Department of Neurology, University Hospital Münster, Münster, Germany., Giovannoni G; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Drudge C; EVERSANA™, Burlington, Ontario, Canada., Haltner A; EVERSANA™, Sydney, Nova Scotia, Canada., Worthington E; EVERSANA™, Burlington, Ontario, Canada., Zhao M; EVERSANA™, Burlington, Ontario, Canada., Brennan R; Novartis Ireland, Dublin, Ireland., Häring DA; Novartis Pharma AG, Basel 4002, Switzerland., Cameron C; EVERSANA™, Sydney, Nova Scotia, Canada., Adlard N; Novartis Pharma AG, Basel 4002, Switzerland. Electronic address: nicholas.adlard@novartis.com.

Publikováno v: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2022 Oct; Vol. 66, pp. 104031. Date of Electronic Publication: 2022 Jul 04.